Somewhere in the last year you probably heard the phrase. A window. A window of opportunity for hormone therapy, and the strong suggestion that it might be closing, or already closed, or that you should have known about it sooner.
If you're 58 and just started putting words to what's been happening, that phrase lands like a door shutting down the hall.
So let's slow down and say what the window actually is, because the real version is more useful than the headline version — and considerably less cruel.
What researchers actually mean
The window refers to when hormone therapy is started relative to menopause, not whether you deserve it.
The general framing across major menopause guidelines is this: for healthy women with symptoms, starting hormone therapy before age 60, or within about ten years of your final period, is where the benefits most clearly outweigh the risks. That's the shape of it. Not a hard border. A stretch of road where the math is most favorable.
Researchers call it the timing hypothesis. It came out of trying to understand why early studies produced such alarming headlines in the early 2000s while the women in clinic — the ones actually taking hormones in their early fifties — kept doing well.
The answer turned out to be partly about age. Many women in those early studies started hormone therapy in their late sixties and seventies, sometimes two decades past menopause. That's a different body, a different starting point, and it produced different results.
Why timing changes the math
The clearest explanation is cardiovascular.
Estrogen appears to help blood vessels that are still relatively healthy — flexible, smooth-walled, doing their job. Start it in that state and the research suggests it supports what's already working. Some studies have found meaningfully lower coronary artery disease risk in women who started within ten years of menopause.
Start it much later, in vessels where plaque has already built up over twenty years, and you're introducing something into a different environment. The same intervention, a different context, a different result.
That's the whole idea, and it's less mystical than "window" makes it sound. It's not a magic clock. It's that the state of your body when you begin genuinely affects what the treatment does.
There's a similar line of research around bone and brain, though the brain evidence is considerably less settled than the internet suggests. Bone protection is well established — hormone therapy prevents the rapid bone loss that follows menopause, which is one reason guidelines support its use in younger menopausal women.
The part that gets left out
Here's what almost never makes the headline.
The window is a description of where the evidence is strongest. It is not a cutoff, and it is not a verdict on you.
The research papers mention starting hormone therapy after 65, and yet the honest summary is: riskier, and still appropriate for some women. Not "never." Not "you missed it." A different conversation with different math, held with someone who knows how to hold it.
There are women who start later and do well. There are women well inside the window for whom hormone therapy isn't the right call because of their personal history. The window is one input. It's not the decision.
If you're reading this at 62 thinking you blew it, you didn't blow anything. You were very likely never told this existed. A generation of women weren't — the fallout from those early studies scared off patients and clinicians alike for the better part of twenty years. That's a failure of medical communication, not of you.
If you think you're inside the window
Then the useful thing to know is that hesitation has a cost too.
Not urgency — nothing here needs to happen this week. But if you've been sitting on symptoms for three years waiting to feel bad enough to justify a conversation, that waiting is itself a decision, and it's using up the part of the timeline where your options are widest.
The FDA removed the boxed warning from hormone therapy labeling in late 2025, which tells you something about how the understanding has shifted. Many women are still operating on information from 2002, and so are some of their doctors.
You don't need to have decided anything to have the conversation. Getting evaluated is not a commitment to treatment.
If you think you're outside it
Then the useful thing to know is that "outside the window" is not the same as "out of options."
It means the conversation gets more individual. Your cardiovascular history matters more. Route of administration matters more — transdermal delivery carries different risk than oral. Dose matters more. What you're actually trying to treat matters more.
It also means the alternatives deserve a real look rather than a shrug. Localized treatment for genitourinary symptoms, for instance, carries a very different risk profile than systemic therapy, and it's often the thing bothering women most.
What you shouldn't accept is being told there's nothing to discuss. There's almost always something to discuss.
What we'd actually do
If you came in tomorrow, we'd start with when your last period was, what you're experiencing now, what your cardiovascular and family history look like, and what you're hoping to get back. Then we'd tell you honestly where you sit relative to the evidence — including if the answer is that hormone therapy isn't your best option.
Some women leave with a plan. Some leave with a clearer picture and a decision to wait. Both are real outcomes.
What you shouldn't leave with is the feeling that you asked too late.
Schedule your free 30 minute consult today.
Bring your questions, including the ones you think are too basic. Especially those.
This article is general education, not medical advice. Whether hormone therapy is appropriate for you depends on your health history, and that determination belongs with a qualified provider who knows it.
Sources
- 2022 Hormone Therapy Position Statement, The Menopause Society: https://menopause.org/wp-content/uploads/press-release/ht-position-statement-release.pdf
- Initiation of Hormone Therapy After Age 65 Remains Risky but Still Works for Some Women, The Menopause Society: https://menopause.org/press-releases/initiation-of-hormone-therapy-after-age-65-remains-risky-but-still-works-for-some-women
- The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review (PMC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872825/
- Hormone Therapy patient education, The Menopause Society: https://menopause.org/patient-education/menopause-topics/hormone-therapy